And. D. DC-based vaccine antigen pulsing. DC co-cultured with HHP-treated tumor cells and matured by a TLR 9 agonist exhibited higher cell surface manifestation of maturation markers and production of IL-12 and other cytokines, when compared with the DC pulsed with irradiated tumor cells. Immunization with DC cell-based vaccines pulsed with HHP-treated tumor cells induced high defense responses, recognized by increased spleen cell cytotoxicity and elevated IFN production. The DC-based vaccine pulsed with HHP-treated tumor cells coupled with docetaxel chemotherapy significantly inhibited growth of the two TC-1 and TRAMP-C2 tumors. Our outcomes indicate that DC-based vaccines pulsed with HHP-inactivated tumor cells can be a suitable device for chemoimmunotherapy, particularly with regards to the results that badly immunogenic TRAMP-C2 tumors were susceptible to this treatment modality. Keywords: dendritic cells, docetaxel, high hydrostatic pressure, immunotherapy, cancer == Introduction == Cancer immunotherapy, especially when coupled with other restorative modalities such as chemotherapy, is usually an attractive method to cancer treatment. Synergistic effects of combinations of immunotherapy and chemotherapy have already been demonstrated in several pre-clinical and clinical studies (1, 2). Dendritic cells (DCs) are key players in the defense response as they are able to catch antigens with their pattern-recognition receptors, to process and present them to nave T-cells, inducing their activation (3), and thus building an important bridge between innate and adaptive reactions. The possibility of their particular generationin vitroenabled their make use of for immunotherapy of malignancy (4), and a number of clinical trials have been performed in 4-HQN the last decade (5, 6). Typically, an autologous dendritic cell-based vaccine representsin vitrocultured dendritic cells pulsed with tumor antigens that can be in the form of tumor cells with following DC maturation. For DC pulsing, tumor cells can be inactivated by their lysis (ultrasonic treatment, repeated freeze-thaw), lethal irradiation or other methods before combining them with DC. Selection of the optimal inactivation method can be important for DC vaccine optimization, together with choice of proper maturation-inducing agents. Therefore , a significant work has also been invested in increasing the immunogenicity of dying malignancy cells utilized for vaccine production. Until now a number of chemotherapeutic real estate agents [anthracyclines (7), oxaliplatin, platinum complexes (8), bortezomib (9)] and physical modalities [UV-C, irradiation (10), HHP] have already been identified as inducers of immunogenic cell death (ICD). ICD is characterized by the cell-surface expression and release of damage associated molecular patterns (DAMPs). DAMPs identified to be important for ICD include surface exposed chaperone protein calreticulin (CRT) and heat surprise proteins 70 (HSP70) and 90 (HSP90), actively secreted ATP and passively introduced high-mobility group box 1 protein (HMGB1). These indicators can switch on innate immunity and, significantly, interact with phagocytosis-related receptors, purinergic receptors and pattern-recognition receptors expressed by DCs and thereby activate presentation of tumor antigens Isl1 to To cells. Substantial hydrostatic 4-HQN pressure (HHP) have been demonstrated like a convenient device for tumor cell inactivation preserving their particular immunogenic capability (11, 12). Recently, induction of ICD by HHP has been shown in a number of human tumor cell lines. HHP-treated cells were able to stimulate monocyte-derived DC maturation, and DC co-cultured with HHP-treated tumor cells were 4-HQN able to stimulate T cell activationin vitro. These motivating results suggest that HHP can be an important device for tumor cell inactivation before their particular use pertaining to DC pulsing or since cellular vaccines (13). Chemotherapeutic drugs impact rapidly growing cells and, as a result, cause security damage to cells of the defense mechanisms. In this regard, they may be considered immunosuppressive. 4-HQN However , there is certainly increasing proof that a few cancer chemotherapies may actually aid the immunotherapy by activating the immune system rather than suppressing it (14, 15). Chemotherapeutic medicines such as cyclophosphamide, doxorubicin, paclitaxel or docetaxel (16) were reported to enjoy immunomodulatory activities and appeared to be suitable for chemoimmunotherapy (17, 18). Docetaxel is actually a widely used chemotherapeutic drug and represents a first-line chemotherapy pertaining to metastatic castration-resistant prostate malignancy (19, 20). The autologous dendritic cell-based vaccines are intensively researched as an immunotherapy pertaining to prostate malignancy, and the 1st cellular immunotherapy.